FDA provides minimal comment on Grail cancer test before advisory committee meeting

The FDA typically releases briefing documents that give a clear stance on a drug or diagnostic's safety and efficacy before its advisory committee convenes.

In the upcoming meeting concerning Grail's cancer detection test, the agency has released only a brief statement, offering little insight into its assessment.

The limited commentary leaves stakeholders awaiting the committee's discussion to gauge the test's regulatory prospects.